KR950700286A - 2,3,4,5-테트라하이드로-1H-3-벤즈아제핀 및 약제학적으로 허용가능한 이의 산 부가염(2,3,4,5-Tetrahydro-1H-3-benzazepines and pharmaceutically acceptable acid addition salts thereof) - Google Patents

2,3,4,5-테트라하이드로-1H-3-벤즈아제핀 및 약제학적으로 허용가능한 이의 산 부가염(2,3,4,5-Tetrahydro-1H-3-benzazepines and pharmaceutically acceptable acid addition salts thereof)

Info

Publication number
KR950700286A
KR950700286A KR1019940702944A KR19940702944A KR950700286A KR 950700286 A KR950700286 A KR 950700286A KR 1019940702944 A KR1019940702944 A KR 1019940702944A KR 19940702944 A KR19940702944 A KR 19940702944A KR 950700286 A KR950700286 A KR 950700286A
Authority
KR
South Korea
Prior art keywords
tetrahydro
pharmaceutically acceptable
acid addition
addition salts
acceptable acid
Prior art date
Application number
KR1019940702944A
Other languages
English (en)
Other versions
KR100255739B1 (ko
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of KR950700286A publication Critical patent/KR950700286A/ko
Application granted granted Critical
Publication of KR100255739B1 publication Critical patent/KR100255739B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
KR1019940702944A 1992-02-24 1993-02-05 2,3,4,5-테트라하이드로-1h-3-벤즈아제핀과 약제학적으로 허용되는 이의 산 부가염 및 이들을 함유하는 약제학적 조성물 KR100255739B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DK92233A DK23392D0 (da) 1992-02-24 1992-02-24 Heterocykliske forbindelser, deres anvendelse og fremstilling
DK233/92 1992-02-24
PCT/DK1993/000041 WO1993017012A1 (en) 1992-02-24 1993-02-05 2,3,4,5-tetrahydro-1h-3-benzazepines and pharmaceutically acceptable acid addition salts thereof

Publications (2)

Publication Number Publication Date
KR950700286A true KR950700286A (ko) 1995-01-16
KR100255739B1 KR100255739B1 (ko) 2000-05-01

Family

ID=8091236

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019940702944A KR100255739B1 (ko) 1992-02-24 1993-02-05 2,3,4,5-테트라하이드로-1h-3-벤즈아제핀과 약제학적으로 허용되는 이의 산 부가염 및 이들을 함유하는 약제학적 조성물

Country Status (23)

Country Link
EP (1) EP0628039B1 (ko)
JP (1) JPH07504172A (ko)
KR (1) KR100255739B1 (ko)
AT (1) ATE152450T1 (ko)
AU (1) AU667878B2 (ko)
BG (1) BG62208B1 (ko)
CA (1) CA2130678C (ko)
CZ (1) CZ288626B6 (ko)
DE (1) DE69310353T2 (ko)
DK (2) DK23392D0 (ko)
ES (1) ES2102019T3 (ko)
FI (1) FI113770B (ko)
GR (1) GR3023896T3 (ko)
HU (1) HU221314B1 (ko)
IL (1) IL104657A (ko)
NO (1) NO310193B1 (ko)
NZ (1) NZ249465A (ko)
RO (1) RO116088B1 (ko)
RU (1) RU2114839C1 (ko)
SK (1) SK281390B6 (ko)
UA (1) UA34451C2 (ko)
WO (1) WO1993017012A1 (ko)
ZA (1) ZA931099B (ko)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69521122T2 (de) * 1994-03-16 2002-03-07 Cenes Ltd 2,3,4,5-tetrahydro-1h-3-benzazepin säure-additions-salze
CN1200121A (zh) * 1995-09-15 1998-11-25 诺沃挪第克公司 2,3,4,5－四氢－1h－3－苯并氮杂䓬化合物的酸加成盐
GB0130576D0 (en) * 2001-12-20 2002-02-06 Cenes Ltd Dopamine D1 receptor agonist pro-drug compounds & derivatives
LT3842420T (lt) 2012-10-25 2023-02-27 Tetra Discovery Partners Llc Pde4 heteroarilo inhibitoriai
WO2015048407A1 (en) * 2013-09-26 2015-04-02 Tetra Discovery Partners, LLC Heteroaryl inhibitors of pde4

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK180485D0 (da) * 1985-04-22 1985-04-23 Novo Industri As Nitrogenholdige forbindelser
DK325188D0 (da) * 1988-06-15 1988-06-15 Novo Industri As Hidtil ukendte benzazepinderivater
DK67489D0 (da) * 1989-02-14 1989-02-14 Novo Industri As Nye benzazepinderivater

Also Published As

Publication number Publication date
HUT71127A (en) 1995-11-28
BG98993A (bg) 1995-05-31
WO1993017012A1 (en) 1993-09-02
DE69310353D1 (de) 1997-06-05
IL104657A (en) 1999-11-30
DE69310353T2 (de) 1997-10-02
RO116088B1 (ro) 2000-10-30
FI943875A (fi) 1994-08-23
AU667878B2 (en) 1996-04-18
ATE152450T1 (de) 1997-05-15
SK281390B6 (sk) 2001-03-12
NO943123L (no) 1994-08-24
CA2130678A1 (en) 1993-08-25
GR3023896T3 (en) 1997-09-30
SK100094A3 (en) 1995-04-12
CA2130678C (en) 2004-04-20
JPH07504172A (ja) 1995-05-11
RU2114839C1 (ru) 1998-07-10
EP0628039A1 (en) 1994-12-14
NO310193B1 (no) 2001-06-05
BG62208B1 (bg) 1999-05-31
KR100255739B1 (ko) 2000-05-01
CZ288626B6 (cs) 2001-08-15
IL104657A0 (en) 1993-06-10
NZ249465A (en) 1996-02-27
HU9402434D0 (en) 1994-10-28
CZ198894A3 (en) 1995-10-18
DK0628039T3 (da) 1997-12-08
HU221314B1 (en) 2002-09-28
FI943875A0 (fi) 1994-08-23
RU94040719A (ru) 1996-07-10
NO943123D0 (no) 1994-08-24
UA34451C2 (uk) 2001-03-15
ZA931099B (en) 1994-08-17
ES2102019T3 (es) 1997-07-16
AU3626593A (en) 1993-09-13
FI113770B (fi) 2004-06-15
DK23392D0 (da) 1992-02-24
EP0628039B1 (en) 1997-05-02

Similar Documents

Publication Publication Date Title
FI935134A (fi) Substituerade 3-aminokinuklidiner
ATE168007T1 (de) Zur behandlung von erkrankungen des zentralnervensystems verwendbare benzimidazole
PH25571A (en) Alpha'-alkyl-4-amino-3-quinolinemethanols, 1-(4-aralkylamino-3-quinolinyl) alaknones, their use as medicaments
DE69523155D1 (de) Benzimidazolonderivate mit zentraler dopaminerger aktivität
FI970469A0 (fi) Bentsimidatsolijohdannaisia, joilla on dopaminerginen aktiivisuus
KR950700286A (ko) 2,3,4,5-테트라하이드로-1H-3-벤즈아제핀 및 약제학적으로 허용가능한 이의 산 부가염(2,3,4,5-Tetrahydro-1H-3-benzazepines and pharmaceutically acceptable acid addition salts thereof)

Legal Events

Date Code Title Description
A201 Request for examination
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20040205

Year of fee payment: 5

LAPS Lapse due to unpaid annual fee